HomeCompareERYP vs STAG

ERYP vs STAG: Dividend Comparison 2026

ERYP yields 256.41% · STAG yields 3.44%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ERYP wins by $541.21M in total portfolio value
10 years
ERYP
ERYP
● Live price
256.41%
Share price
$0.78
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$541.22M
Annual income
$306,262,465.48
Full ERYP calculator →
STAG
STAG Industrial Inc.
● Live price
3.44%
Share price
$36.09
Annual div
$1.24
5Y div CAGR
0.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$18.3K
Annual income
$462.22
Full STAG calculator →

Portfolio growth — ERYP vs STAG

📍 ERYP pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodERYPSTAG
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ERYP + STAG cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ERYP pays
STAG pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ERYP
Annual income on $10K today (after 15% tax)
$21,794.87/yr
After 10yr DRIP, annual income (after tax)
$260,323,095.66/yr
STAG
Annual income on $10K today (after 15% tax)
$292.45/yr
After 10yr DRIP, annual income (after tax)
$392.89/yr
At 15% tax rate, ERYP beats the other by $260,322,702.77/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ERYP + STAG for your $10,000?

ERYP: 50%STAG: 50%
100% STAG50/50100% ERYP
Portfolio after 10yr
$270.62M
Annual income
$153,131,463.85/yr
Blended yield
56.59%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on STAG right now

ERYP
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
1.9
Piotroski
2/9
STAG
Analyst Ratings
9
Buy
9
Hold
3
Sell
Consensus: Buy
Price Target
$45.00
+24.7% upside vs current
Range: $39.00 — $59.00
Altman Z
1.2
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ERYP buys
0
STAG buys
0
No recent congressional trades found for ERYP or STAG in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricERYPSTAG
Forward yield256.41%3.44%
Annual dividend / share$2.00$1.24
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0.3%
Portfolio after 10y$541.22M$18.3K
Annual income after 10y$306,262,465.48$462.22
Total dividends collected$516.37M$4.0K
Payment frequencyquarterlymonthly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: ERYP vs STAG ($10,000, DRIP)

YearERYP PortfolioERYP Income/yrSTAG PortfolioSTAG Income/yrGap
1← crossover$36,341$25,641.03$10,665$345.09+$25.7KERYP
2$125,971$87,086.09$11,364$357.70+$114.6KERYP
3$416,912$282,122.92$12,098$370.43+$404.8KERYP
4$1,318,722$872,626.36$12,869$383.28+$1.31MERYP
5$3,990,640$2,579,607.07$13,677$396.23+$3.98MERYP
6$11,565,551$7,295,566.53$14,524$409.27+$11.55MERYP
7$32,135,691$19,760,551.21$15,411$422.41+$32.12MERYP
8$85,699,274$51,314,084.97$16,339$435.61+$85.68MERYP
9$219,589,910$127,891,686.63$17,311$448.89+$219.57MERYP
10$541,223,669$306,262,465.48$18,327$462.22+$541.21MERYP

ERYP vs STAG: Complete Analysis 2026

ERYPStock

ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France.

Full ERYP Calculator →

STAGREIT

STAG Industrial, Inc. (NYSE: STAG) is a real estate investment trust focused on the acquisition and operation of single-tenant, industrial properties throughout the United States. By targeting this type of property, STAG has developed an investment strategy that helps investors find a powerful balance of income plus growth.

Full STAG Calculator →
📬

Get this ERYP vs STAG comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ERYP vs SCHDERYP vs JEPIERYP vs OERYP vs KOERYP vs MAINERYP vs PLDERYP vs EQRERYP vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.